- Home
- CRVS vs IMMR Comparison
CRVS vs IMMR Comparison
Compare CRVS & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- IMMR
- Stock Information
- Founded
- CRVS 2014
- IMMR 1993
- Country
- CRVS United States
- IMMR United States
- Employees
- CRVS N/A
- IMMR N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- IMMR Computer peripheral equipment
- Sector
- CRVS Health Care
- IMMR Technology
- Exchange
- CRVS Nasdaq
- IMMR Nasdaq
- Market Cap
- CRVS 206.5M
- IMMR 231.6M
- IPO Year
- CRVS 2016
- IMMR 1999
- Fundamental
- Price
- CRVS $3.63
- IMMR $7.38
- Analyst Decision
- CRVS Strong Buy
- IMMR Strong Buy
- Analyst Count
- CRVS 3
- IMMR 2
- Target Price
- CRVS $15.67
- IMMR $12.25
- AVG Volume (30 Days)
- CRVS 906.6K
- IMMR 363.0K
- Earning Date
- CRVS 05-05-2025
- IMMR 05-07-2025
- Dividend Yield
- CRVS N/A
- IMMR 5.18%
- EPS Growth
- CRVS N/A
- IMMR 57.07
- EPS
- CRVS N/A
- IMMR 2.04
- Revenue
- CRVS N/A
- IMMR $163,133,000.00
- Revenue This Year
- CRVS N/A
- IMMR $988.71
- Revenue Next Year
- CRVS N/A
- IMMR $109.72
- P/E Ratio
- CRVS N/A
- IMMR $3.59
- Revenue Growth
- CRVS N/A
- IMMR 338.21
- 52 Week Low
- CRVS $1.43
- IMMR $6.47
- 52 Week High
- CRVS $10.00
- IMMR $13.94
- Technical
- Relative Strength Index (RSI)
- CRVS 55.04
- IMMR 48.93
- Support Level
- CRVS $3.15
- IMMR $6.88
- Resistance Level
- CRVS $3.78
- IMMR $7.25
- Average True Range (ATR)
- CRVS 0.25
- IMMR 0.32
- MACD
- CRVS 0.12
- IMMR 0.04
- Stochastic Oscillator
- CRVS 87.90
- IMMR 87.78
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.